SG Americas Securities
ZYNE

SG Americas Securities’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

SG Americas Securities’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-42,463
Closed -$321K – 3489
2019
Q3 		$321K Buy
42,463
+26,990
+174% +$304K ﹤0.01% 2123
2019
Q2 		$210K Buy
+15,473
New +$179K ﹤0.01% 2391
2017
Q2 		– Sell
-9,364
Closed -$188K – 3612
2017
Q1 		$188K Buy
+9,364
New +$186K ﹤0.01% 2483

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ZCA
Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

SG Americas Securities's ZYNE Position: Q4 2019 in Review

SG Americas Securities sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2019, closing a stake of 42,463 shares — an estimated $321K sold.

SG Americas Securities first reported a position in ZYNE in Q1 2017 and held it in 3 quarters. The position peaked at $321K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

  • SG Americas Securities reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2019 after selling out during the quarter.
  • SG Americas Securities sold 42,463 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $321K.
  • SG Americas Securities first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 3 quarters.
  • SG Americas Securities's Zynerba Pharmaceuticals, Inc position peaked at $321K in Q3 2019.
  • 79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on SG Americas Securities's 13F filing for Q4 2019, filed 28 Jan 2020.